Post-COVID-19-Treatment Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033476

Enrollment

Registered

2024-02-01

Start date

2024-03-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U09.9

Interventions

Group 1: Cognitive-behavioral single- and group treatment (interlocked), consisting of 8 group therapy and 6 single therapy sessions, which treat psychological mechanisms of symptom maintenance (e.g.,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Post-COVID-Syndrom / Post-Covid-19-Condition based on WHO-criteria (2021)

Exclusion criteria

Exclusion criteria: Admission to intensive care or mechanical ventilation during COVID-19, somatic contradictions against exposure therapy, acute psychotic or manic symptoms according to DSM-5, acute substance use while fulfilling criteria of a substance use disorder (middle or severe) according to DSM-5; acute severe depressive disorder according to DSM-5, acute danger for self or others; inability to participate in sessions (physical, organizational), parallel psychotherapeutic treatment or participation in another intervention study and on-going criminal proceedings

Design outcomes

Primary

Measure	Time frame
Intensity of body complaints (incl. fatigue, breathing difficulties, circulatory problems, Post-Exertion-Symptoms) with Patient Health Questionnaire - 15 (PHQ-15), Fatigue Severity Scale (FSS), Scales "Breathing" and "Circulation" of the Symptom Burden Questionnaire - Long Covid (SBQ-LC), Scale "Post-Exertion Malaise" of the DePaul Symptom Questionnaire-2 at T0, T1, T2, T3; Symptom-related thoughts, feelings, and behaviors (symptom burden) with Somatic Symptom Disorder B - Criteria Scale (SSD-12) at T0, T1, T2, T3; Session rating with Session Rating Scale (SRS) and Group Therapy Session Evaluation form-P/T (GTS-P/T) after each single and group session; Side effects of treatment with Inventory for the balanced assessment of Negative Effects of Psychotherapy (INEP) at T1 or T2	—

Measure

Time frame

Intensity of body complaints (incl. fatigue, breathing difficulties, circulatory problems, Post-Exertion-Symptoms) with Patient Health Questionnaire - 15 (PHQ-15), Fatigue Severity Scale (FSS), Scales "Breathing" and "Circulation" of the Symptom Burden Questionnaire - Long Covid (SBQ-LC), Scale "Post-Exertion Malaise" of the DePaul Symptom Questionnaire-2 at T0, T1, T2, T3; Symptom-related thoughts, feelings, and behaviors (symptom burden) with Somatic Symptom Disorder B - Criteria Scale (SSD-12) at T0, T1, T2, T3; Session rating with Session Rating Scale (SRS) and Group Therapy Session Evaluation form-P/T (GTS-P/T) after each single and group session; Side effects of treatment with Inventory for the balanced assessment of Negative Effects of Psychotherapy (INEP) at T1 or T2

—

Secondary

Measure	Time frame
Disease coping with Brief Illness Perception Questionnaire (B-IPQ) at T0, T1, T2, T3; Somatosensory Amplification with Somatosensory Amplification Scale (SSAS) at T0, T1, T2, T3; Construkts of the somatoform spectrum of the Hierarchical Taxonomy of Psychopathology (HiTOP) with short-scale for the somatoform spectrum of the HiTOP zu T0, T1, T2, T3; Treatment expectations with Credibility/Expectancy Questionnaire (CEQ) at T0; Anxiety Symptoms with Generalized Anxiety Disorder Scale-7 (GAD-7) at T0, T1, T2, T3; Depressive Symptoms with Patient Health Questionnaire-9 (PHQ-9) at T0, T1, T2, T3; Impairments of work productivity and activity with Work Productivity and Activity Impairment Questionnaire (WPAI) at T0, T1, T2, T3	—

Measure

Time frame

Disease coping with Brief Illness Perception Questionnaire (B-IPQ) at T0, T1, T2, T3; Somatosensory Amplification with Somatosensory Amplification Scale (SSAS) at T0, T1, T2, T3; Construkts of the somatoform spectrum of the Hierarchical Taxonomy of Psychopathology (HiTOP) with short-scale for the somatoform spectrum of the HiTOP zu T0, T1, T2, T3; Treatment expectations with Credibility/Expectancy Questionnaire (CEQ) at T0; Anxiety Symptoms with Generalized Anxiety Disorder Scale-7 (GAD-7) at T0, T1, T2, T3; Depressive Symptoms with Patient Health Questionnaire-9 (PHQ-9) at T0, T1, T2, T3; Impairments of work productivity and activity with Work Productivity and Activity Impairment Questionnaire (WPAI) at T0, T1, T2, T3

—

Countries

Germany

Contacts

Public ContactKaroline Sophie Sauer

Johannes Gutenberg-Universität Mainz, Abteilung für Klinische Psychologie, Psychotherapie und Experimentelle Psychopathologie

karsauer@uni-mainz.de+4961313939179

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026